MOUSE MODELS OF CANCER THERAPIES GROUP

PRECLINICAL & TRANSLATIONAL RESEARCH
Mouse Models of Cancer Therapy

LAURA SOUCEK
Principal Investigator
Biosketch

Our group focuses on the pleiotropic and ubiquitous Myc oncoprotein, whose deregulation is implicated in almost all human cancers. The technical challenges of targeting nuclear transcription factors such as Myc –and the concern regarding potential side effects– had until recently precluded any preclinical validation of Myc inhibition as a possible therapeutic strategy.

Over the past few years, we have demonstrated in several mouse models that Myc inhibition has a dramatic therapeutic impact across several tumor types, with very mild and reversible side effects in normal tissue.

Encouraged by our results in mice, we are now interested in developing viable, non-toxic pharmacological options for Myc targeting in the clinic. To do so, we have created a spin-off company, Peptomyc S.L., for the development of Myc-inhibiting peptides for cancer therapy. Our laboratory in partnership with Peptomyc is currently validating our novel approach against notoriously difficult-to-treat cancers that are resistant to standard treatments and in dire need of new therapeutic avenues (i.e. KRAS-driven Non-Small Cell Lung Cancer, glioblastoma, and metastatic triple negative breast cancer).

Our group has continued to contribute to groundbreaking science by publishing in journals of international prestige. One particular highlight for 2019 is a paper describing key studies for advancing our Myc inhibitor mini-protein Omomyc towards the clinic (Beaulieu et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019). This publication was very well received by the scientific community and highlighted in Nature Reviews Cancer and Nature Reviews Drug Discovery as a potential seminal milestone towards the clinical application of our first-in-class Myc inhibitor.

STRATEGIC GOALS

  • Validation of new Omomyc-based cell penetrating peptides for cancer therapy.
  • Preclinical validation of novel anti-Myc therapies in breast, brain, lung, neuroblastoma, melanoma, colorectal cancer and multiple myeloma.
  • Define the role of Myc in promoting cancer immune evasion.
  • Elucidate the role of the Myc network in Max-defective gastrointestinal stromal tumors (GISTs), Small-Cell Lung Cancer (SCLC) and Pheochromocytomas (PCC).

 


HIGHLIGHTS

  • The publication by Beaulieu et al. in Science Translational Medicine showing that the Myc inhibitory peptide Omomyc can penetrate cancer cells and act against tumors in vivo, demonstrating its potential for clinical development, has generated a great deal of media coverage.
  • Laura Soucek and Jonathan Whitfield were guest editors of a special edition of Current Opinion in Pharmacology on Peptides in Cancer.
  • Additional new funding granted, notably from La Marató and FIS (ISCIII).
  • 2 new patent applications were filed by Laura Soucek’s laboratory.

 


TEAM

  • Principal Investigator
    • Laura Soucek
  • Staff Scientist
    • Jonathan R. Whitfield
  • Postdoctoral Fellows
    • Jastrijan Kaur
    • Mariano F. Zacarias
  • Graduate Student
    • Sandra Martínez Martin
  • Technicians
    • Virginia Castillo Cano
    • Inmaculada Genesis Martin
    • Erika Serrano del Pozo
  • Fulbright Scholar
    • Jessica Lee Chambers

 


Most relevant scientific publications

  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano del Pozo E, Fiore C, Foradada L, Castillo Cano V, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MA, Whitfield JR, Lavigne P, Soucek L. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019 Mar 20;11(484).
  • Beaulieu ME, Soucek L. Finding MYCure. Mol Cell Oncol. 2019 Jun 20;6(5):e1618178.
  • Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix, Sandra Mancilla R, Fernández Y, Rinas U, Schwartz Jr S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci. 2019 Jul 24.
  • Whitfield JR, Soucek L. Editorial Overview: Peptides in Cancer. Curr Opin Pharmacol. 2019 Jun 27. pii: S1471-4892(19)30045-1.
  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med. 2019 Mar 20;11(484). Link to Abstract
  • Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget. 2018 Apr 10;9(27):18734-18746.
  • Dang C, Reddy EP, Shokat K, and Soucek L. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017 Aug;17(8):502-508.
  • Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivanco A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene. 2017 Oct 5;36(40):5639-5647.
  • Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol. 2017 Feb 23;5:10. eCollection 2017.
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models. Nat Rev Cancer. 2017 Apr;17(4):254-268.
  • Massó-Vallés D, Jauset T, Soucek L. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8.
  • Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation.  Oncotarget. 2016 May 24;7(21):31014-28.
  • Daniel Massó-Vallés, Toni Jauset and Laura Soucek. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. Onlibe Advanced Publication DOI: 10.18632/oncoscience.310. Editorial.
  • Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, Laura Soucek, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.
  • Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi,  Neetu Singh, Laura Soucek, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. Review.
  • Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and Laura Soucek. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.
  • Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, , Joan Seoane, Gerard I Evan, and Laura Soucek. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. Article.
  • Laura Soucek, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.
  • Whitfield J, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.
  • Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and Laura Soucek. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8. Article.
  • Andrew Finch*, Laura Soucek*, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. *Joint first authors
  • Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.
  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.
  • Maria A. Christophorou, Dionisio Martin-Zanca, Laura Soucek, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo.Nature Genetics. 2005 Jul;37(7):718-26. Article.
  • Laura Soucek, Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.
  • Laura Soucek and Gerard Evan. Myc – is this the oncogene from Hell?. Cancer Cell. 2002 June; 1(5): 406-408. Review.
  • Laura Soucek, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis. Cancer Res. 2002; 62: 3507-3510. Article.
  • Soucek L., Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.

All publications

  • Ikemori R, Gabasa M, Duch P, Vizoso M, Bragado P, Arshakyan M, Luis IC, Marín A, Morán S, Castro M, Fuster G, Gea-Sorli S, Jauset T, Soucek L, Montuenga LM, Esteller M, Monsó E, Peinado VI, Gascon P, Fillat C, Hilberg F, Reguart N, Alcaraz J. Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. Cancer Res. 2019 Nov 6.
  • Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix R, Mancilla S, Fernández Y, Rinas U, Schwartz Jr S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci.  2019 Jul 24.
  • Whitfield JR, Soucek L. Editorial Overview: Peptides in Cancer.  Curr Opin Pharmacol. 2019 Jun 27. pii: S1471-4892(19)30045-1.
  • Ramón Y Cajal S, Sancho P, Soucek L, Peinado H, Abad M, Valiente M, Efeyan A, Pardo J, Quesada V, Jimeno J, Duque PM, Antón A, Varela I, Schuhmacher AJ. A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas. Clin Transl Oncol. 2019 Aug 9.
  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano del Pozo E, Fiore C, Foradada L, Castillo Cano V, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MA, Whitfield JR, Lavigne P, Soucek L.  Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy.Sci Trans Med.2019 Mar 20;11(484).
  • Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman S, Vibhakar R. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1 deficient Group 2 Atypical Teratoid Rhabdoid Tumors to suppress tumor growth in vivo.Int J Cancer. 2019 Apr 15;144(8):1983-1995.
  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med. 2019 Mar 20;11(484).
  • Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget. 2018 Apr 10;9(27):18734-18746.
  • Sílvia Casacuberta-Serra and Laura Soucek. Myc and Ras, the Bonnie and Clyde of immune evasion. Translational Cancer Research. 2018 Feb;7(Suppl 4):S457-S459.
  • Dang C, Reddy EP, Shokat K, andSoucek L. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer.  2017 Jun 23. doi: 10.1038/nrc.2017.36.
  • Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivanco A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J and Arribas J. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene.2017 Jun 5. doi: 10.1038/onc.2017.174.
  • Maltais L, Montagne M, Bédard M, Tremblay C, Soucek L and Lavigne P. Biophysical Characterization of the b-HLH-LZ of ΔMax, an Alternatively Spliced Isoform of Max Found in Tumor Cells: Towards the Validation of a Tumor Suppressor Role for the Max Homodimer. PLoS One. 2017 Mar 28;12(3): e0174413. https://doi.org/10.1371/journal.pone.0174413.
  • Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front. Cell Dev. Biol., 23 February 2017.
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models. Nat Rev Cancer. 2017 Jan 20. doi: 10.1038/nrc.2016.140.
  • Beaulieu ME, Jauset T, Massó-Vallés D, Soucek L*and Whitfield JR. Mouse Models in Personalized Cancer Medicine. Chapter 6 of Cancer genetics and Genomics for Personalized Medicine. 2017. ISBN: 9789814669887. Book Chapter. *Corresponding author.
  • Massó-Vallés D, Jauset T, Soucek L. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8.
  • Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation.  Oncotarget. 2016 May 24;7(21):31014-28.
  • Daniel Massó-Vallés, Toni Jauset and Laura Soucek. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. Onlibe Advanced Publication DOI: 10.18632/oncoscience.310. Editorial.
  • Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, Laura Soucek, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.
  • Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi,  Neetu Singh, Laura Soucek, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. Review.
  • Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and Laura Soucek. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.
  • Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, , Joan Seoane, Gerard I Evan, and Laura Soucek. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. Article.
  • Laura Soucek, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.
  • Whitfield J, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.
  • Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and Laura Soucek. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8. Article.
  • Andrew Finch*, Laura Soucek*, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. *Joint first authors
  • Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.
  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.
  • Maria A. Christophorou, Dionisio Martin-Zanca, Laura Soucek, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo.Nature Genetics. 2005 Jul;37(7):718-26. Article.
  • Laura Soucek, Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.
  • Laura Soucek and Gerard Evan. Myc – is this the oncogene from Hell?. Cancer Cell. 2002 June; 1(5): 406-408. Review.
  • Laura Soucek, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis. Cancer Res. 2002; 62: 3507-3510. Article.
  • Soucek L., Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.